← Leaderboards
Elahe A Mostaghel
Fred Hutchinson Cancer Research Center
$1,491,129
Attributed
$1,491,129
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $200.4K · FY2006–17$250K$187.5K$125K$62.5K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$1,491,129 · 3
By mechanism
P50$846,224 · 2
K23$644,905 · 1
Top collaborators
No co-investigators on record.
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Mark Garzotto$1,394,008
- Peter Nelson$3,139,960
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseClinical TrialsTissuesTumorAndrogen ReceptorNeoplastic CellPathway InteractionsResponseGrowthMalignant Neoplasm Of ProstateAndrogensResistanceMediatingTreatment StrategyAnabolismLigandsLengthLigand Binding DomainMetastatic Prostate CancerExposure ToExhibitsEffective TherapyEnzymesHour
Grant awards (10)
Exploiting Mechanisms of Response and Resistance to Next Generation Androgen Pathway Antagonists$200,423
P50 · FY2017 · CA · contact PI
Exploiting Mechanisms of Response and Resistance to Next Generation Androgen Pathway Antagonists$199,440
P50 · FY2016 · CA · contact PI
Exploiting Mechanisms of Response and Resistance to Next Generation Androgen Pathway Antagonists$126,027
P50 · FY2015 · CA · contact PI
Exploiting Mechanisms of Response and Resistance to Next Generation Androgen Pathway Antagonists$119,938
P50 · FY2014 · CA · contact PI
Exploiting Mechanisms of Response and Resistance to Next Generation Androgen Pat$200,396
P50 · FY2013 · CA · contact PI
In Vivo Efficacy of Multi-Targeted Androgen Inhibition as Prostate Cancer Therapy$107,065
K23 · FY2010 · CA · contact PI
In Vivo Efficacy of Multi-Targeted Androgen Inhibition as Prostate Cancer Therapy$134,460
K23 · FY2009 · CA · contact PI
In Vivo Efficacy of Multi-Targeted Androgen Inhibition as Prostate Cancer Therapy$134,460
K23 · FY2008 · CA · contact PI
In Vivo Efficacy of Multi-Targeted Androgen Inhibition as Prostate Cancer Therapy$134,460
K23 · FY2007 · CA · contact PI
In Vivo Efficacy of Multi-Targeted Androgen Inhibition as Prostate Cancer Therapy$134,460
K23 · FY2006 · CA · contact PI